Safety of Long-Acting β-Agonists
TO THE EDITOR:
The meta-analysis by Salpeter and colleagues (1) raises concerns over the long-term safety of LABAs in patients with asthma. However, the authors are incorrect in stating that “[i]f long-acting β-agonists were removed …
RSS Feeds









